Genetic characterization of accessory genes from human immunodeficiency virus type 1 group O strains

AIDS Research and Human Retroviruses

Volumn 14, Issue 11, 1998, Pages 951-961

  Bibollet Ruche, Frédéric ^a   Loussert Ajaka, Ibtissam ^b   Simon, François ^b   Mboup, Souleymane ^c   Ngole, Eitel Mpoudi ^d   Saman, Eric ^e   Delaporte, Eric ^a   Peeters, Martine ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d Centre Hospitalier Militaire   (Cameroon)

^e INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN; VIF PROTEIN; VPR PROTEIN; VPU PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; VIRUS GENE; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0032551607     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.951     Document Type: Article

References (79)

1. De Leys R, Vanderborght B, Vanden Haesevelde M, Heyndrickx, L, van Geel A, Wauters C, Bernaerts R, Saman E, Nijs P, Willems B, Taelman H, van der Groen G, Piot P, Tersmette T, Huisman JG, and Van Heuverswyn H: Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J Virol 1990;64:1207-1216.
2. Gürtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L, Tsague JM, and Kaptue L: A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994;68:1581-1585.
3. Vanden Haesevelde M, Decourt JL, De Leys RJ, Vanderbortght B, van der Groen G, Van Heuverswijn H, and Saman E: Genomic cloning and complete sequence analysis of a highly divergent human immunodeficiency virus isolate. J Virol 1994;68:1586-1596.
4. Janssens W, Nkengasong JN, Heyndrickx L, Fransen K, Ndumbe PM, Delaporte E, Peeters M, Perret J-L, Ndoumou A, Atende C, Piot P, and van der Groen G: Further evidence of the presence of genetically aberrant strains in Cameroon and Gabon. AIDS 1994;8:1012-1013.
5. Mauclère P, Loussert-Ajaka I, Damond F, Fagot P, Souquières S, Monny Lobe M, Mbopi Keou F-X, Barré-Sinoussi F, Saragosti S, Brun-Vézinet F, and Simon F: Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS 1997;11:445-453.
6. Huet T, Cheyier R, Meyerhans A, Roelants G, and Wain-Hobson S: Genetic organisation of a chimpanzee lentivirus related to HIV-1. Nature (London) 1990;345:356-358.
7. Vanden Haesevelde M, Peeters M, Jannes G, Janssens W, van der Groen G, Sharp PM, and Saman E: Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology 1996;221:346-350.
8. Louwagie J, McCutchan F, Peeters M, Brenan TP, Sanders-Buell E, Eddy GA, van der Groen G, Fransen K, Gershy-Damet G-M, Deleys R, and Burke DS: Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence of multiple genotypes. AIDS 1993;7:769-780.
9. Myers G, Korber B, Hahn BH, Jeang K-T, Mellors JW, McCutchan FE, Henderson LE, and Pavlakis GN (eds.): Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences 1995. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1995.
10. Birx DL, VanCott T, Michael N, McNeil J, Stamatos N, Gillian B, Davis R, Carr J, and McCutchan F: Summary of Track A: Basic science. AIDS 1996;10(Suppl. 3):S85-S106.
11. Alaeus A, Leitner T, Lidman K, and Albert J: Most HTV-1 genetic subtypes have entered Sweden. AIDS 1997;11:199-202.
12. Arnold C, Barlow KL, Parry JV, and Clewley JP: At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England. AIDS Res Hum Retroviruses 1995;11:427-429.
13. Lasky M, Perret JL, Peeters M, Bibollet-Ruche F, Liegeois F, Patrel D, Molinier S, Gras C, and Delaporte E: Presence of multiple non-B subtypes and divergent subtype B strains of HIV-1 in individuals infected after overseas deployment. AIDS 1997;11:43-51.
14. Soto-Ramirez LE, Renjifo B, McLane MF, Marlink R, O'Hara C, Sutthent R, Wasi C, Vithayasai P, Vithayasai V, Apichartpiyakul C, Auewarakul P, Pena Cruz V, Chui D-S, Osathanondh R, Mayer K, Lee T-H, and Essex M: HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996;271: 1291-1293.
15. Pope M, Frankel SS, Mascola JR, Trkola A, Isdell F, Birx DL, Burke DS, Ho DD, and Moore JP: Human immunodeficiency virus type 1 strains of subtypes B and E replicate in culaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J Virol 1997;71:8001-8007.
16. Dittmar MT, Simmons G, Hibbitts S, O'Hare M, Louisirirotchanakul S, Beddows S, Weber J, Clapham PR, and Weiss RA: Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J Virol 1997;71:8008-8013.
17. Peeters M, Gueye A, Mboup S, Bibollel-Ruche F, Ekaza E, Mulanga C, Ouedrago R, Gandji R, Mpele P, Dibanga G, Koumare B, Saidou M, Esu-Williams E, Lombart J-P, Badombena W, LuoN, Vanden Haesevelde M, and Delaporte E: Geographic distribution of HIV-I group O viruses in Africa. AIDS 1997;11:493-498.
18. Peeters M, Gaye A, Mboup S, Badombena W, Bassabi K, Prince-David M, Develoux M, Liegeois F, van der Groen G, Saman E, and Delaporte E: Presence of HIV-1 group O infection in West Africa. AIDS 1990;10:343-344.
19. Hampl H, Sawitzky D, Stöffler-Meilicke M, Groh A, Schmitt M, Eberle J, and Gürtler L: First case of HIV-1 subtype O infection in Germany. Infection 1995;6:369-370.
20. Jonassen TO, Stene-Johansen K, Berg ES, Hungnes O, Lindboe CF, Froland SS, and Grinde B: Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology 1997;231:43-47.
21. Loussert-Ajaka I, Chaix M-L, Korber B, Letourneur F, Gomas E, Allen E, Ly T-D, Brun-Vezinet F, Simon F, and Saragosti S: Variability of human immunodeficiency virus group O strains isolated from Cameroonian patients living in France. J Virol 1995;69: 5640-5649.
22. Soriano V, Guttierez M, Garcia-Lerma G, Mas A, Bravo R, Aguilera O, Perez-Labad ML, and Gonzalez-Lahoz J: First case of group O infection in Spain. Vox Sang 1996;71:66.
23. Centers for Disease Control and Prevention: Identification of HIV-1 group O infection, Los Angeles County, California. MMWR 1996;45:561-564..
24. env immunodominant region of HIV type 1 group O from West Central Africa. AIDS Res Hum Retroviruses 1997;13:901-904.
25. gag sequences from Cameroon and Equatorial Guinea. AIDS Res Hum Retroviruses 1997;13:1155-1158.
26. Korber B, Loussert-Ajaka I, Blouin J, and Saragosti S: A comparison of HIV-1 group M and group O functional and immunogenic domains in the Gag p24 protein and the C2V3 region of the envelope protein: In: Human Retroviruses and AIDS 1996; A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
27. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, and Collman RG: Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: Mutational analysis of a primary HIV-1 isolate. Virology 1994;200:623-631.
28. di Marzio P, Choe S, Ebright M, Knoblauch R, and Landau NR: Mutagenic analysis of cell cycle arrest, nuclear localization, and virion packaging of HIV-I Vpr. J Virol 1995;69:7909-7916.
29. Conclaves J, Korin Y, Zack J, and Gabuzda D: Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol 1996;70:8701-8709.
30. Göttlinger HG, Dorfman T, Cohen E, and Haseltine WA: Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 1993;90:7381-7385.
31. Harrich D, Ulich C, Garcia-Martinez LF, and Gaynor RB: Tat is required for efficient HIV-1 reverse transcription. EMBO J 1997;16:1224-1235.
32. Klimkait T, Strebel K, Hoggan M, Martin M, and Orenstein JM: The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J Virol 1990;64:621-629.
33. Flanelles V, Jowett JBM, Li Q-X, Xie Y, Hahn BH, and Chen ISY: Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol 1996;70:2519-2524.
34. Simon J and Malim MH: The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 1996;70:5297-5305.
35. Vincent MJ and Abdul Jabbar M: The human immunodeficiency virus type 1 Vpu protein: A potential regulator of the proteolysis and protein transport in the mammalian secretory pathway. Virology 1995;213:639-649.
36. Yao XJ, Garzon S, Boisvert F, Haseltine WA, and Cohen EA: The effect of vpu on HIV-1-induced syncytia formation. J Acquir Immune Defic Syndr 1993;6:135-141.
37. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-Ela F, Varani G, Karn J, and Klimkait T: An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-3553.
38. Inouye RT, Du B, Boldt-Houle D, Ferrante A, Park IW, Hammer SM, Duan L, Groopman JE, Pomerantz RJ, and Terwilliger EF: Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J Virol 1997;71:4071-4078.
39. Matsuda Z, Yu X, Yu QC, Lee TH, and Essex M: A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90: 3544-3548.
40. Orsini MJ and Debouck CM: Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm. J Virol 1996;70:8055-8063.
41. Serio D, Rizvi TA, Cartas M, Kalyanaraman VS, Weber IT, Koprowski H, and Srinivasan A: Development of novel anti-HIV1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997;94:3346-3351.
42. Eberle J, Loussert-Ajaka I, Brust S, Zekeng L, Hauser PH, Kaptue L, Knapp S, Damond F. Saragosti S, Simon F, and Gurtler LG: Diversity of the immunodominant epitope of gp41 of HIV-1 subtype O and its validity for antibody detection. J Virol Methods 1997;67:85-91.
43. Delaporte E, Janssens W, Peeters M, Buve A, Dibanga G, Perret JL, Ditsambou V, Georges Courbot MC, Georges A, Bourgeois A, Samb B, Henzel D, Heyndrickx L, Fransen K, Van der Groen G, Larouzé B, and Mbe JR: Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994. AIDS 1996;10:903-910.
44. Bibollet-Ruche F, Brengues C, Galat-Luong A, Galat G, Pourrut X, Vidai N, Veas F, Durand J-P, and Cuny G: Genetic diversity of simian immunodeficiency viruses from West African green monkeys: Evidence for multiple genotypes within populations from the same geographical locale. J Virol 1997;71:307-313.
45. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W-improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
46. Garnier J, Osguthorpe DJ, and Robson B: Analysis of the accuracy and implication of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978;120:97-120.
47. Gibrat JF, Gamier J, and Robson B: Further development of protein secondary structure prediction using information theory. New parameters and consideration of residue pairs. J Mol Biol 1987;198:425-443.
48. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
49. Kimura M: The Neutral Theory of Molecular Evolution. Cambridge University Press, Cambridge, 1983.
50. Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985;39:783-791.
51. Felsenstein J: PHYLIP (phytogeny interference package), version 3.5c. Department of Genetics, University of Washington, Seattle, Washington, 1993.
52. Tiganos E, Yao X-J, Friborg J, Daniel N, and Cohen EA: Putative α-helical structures are involved in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the Ed molecule. J Virol 1997;71:4452-4460.
53. Yao XF, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, and Cohen EA: Mutagenic analysis of human immunodeficiency virus type 1 Vpr: Role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995;69:7032-7044.
54. Garcia JA, Harrich D, Pearson L, Mitsuyasu R, and Gaynor RB: Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 1988;7:3143-3147.
55. Kuppuswamy M, Subramanian T, Srinivasan A, and Chinnadurai G: Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis, Nucleic Acids Res 1989;9: 3551-3561.
56. Mahalingam S, Patel M, Collman RG, and Srinivasan A: The carboxy-terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles. Virology 1995;214: 647-652.
57. Oberste MS and Gonda MA: Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 1992;6:95-102.
58. Macreadie IG, Castelli LA, Hewish DR, Kirkpatrick A, Ward AC, and Azad AA: A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc Natl Acad Sci USA 1995;92:2770-2774.
59. Mahalingam S, Collman RG, Patel M, Monken CE, and Srinivasan A: Role of the conserved dipeptide Gly75 and Cys76 in HIV-1 Vpr function. Virology 1995;210:495-500.
60. Wang L, Mukherjee S, Narayan O, and Zhao LJ: Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1. Gene 1996;178:7-13.
61. Caputo A, Grossi MP, Bozzini R, Rossi C, Belli M, Marconi PC, Barbanti-Brodano G, and Balboni PG: Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Ther 1996;3:235-245.
62. Kamine J, Elangovan B, Subramanian T, Coleman D, and Chinnadurai G: Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996;216:357-366.
63. Ma X-Y, Sova P, Chao W, and Volsky DJ: Cystein residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol 1994;68:1714-1720.
64. Mousumi P and Abdul Jabbar M: Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 1997;232:207-216.
65. Schubert U, Bour S, Ferrer-Montiel AV, Montai M, Maldarell F, and Strebel K: The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996;70:809-819.
66. Hillman K, Qian J, Siegel JN, Roderiquez G, Blackburn R, Manischewitz J, Norcross M, and Golding H: Reduced susceptibility of HIV-1 infection of ethyl-melhanesulfonate-treated CEM subclones correlates with a blocade in their protein kinase C signaling pathway. J Immunol 1992;148:3991-3998.
67. Jokobovits A, Rosenthal A, and Capon DJ: Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J 1990;9:1165-1170.
68. Qatsha KA, Rudolph C, Marne D, Schachtele C, and May WS: Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus type 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci USA 1993;90:4674-4678.
69. Yang X, Conclaves J, and Gabuzda D: Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 1996;271:10121-10129.
70. Braaten D, Franke EK, and Luban J: Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-I) and simian immunodeficiency virus SIVcpzGAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 1996;70:4220-4227.
71. Franke EK, Yuan HE, and Luban J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature (London) 1994;372: 359-362.
72. Colgan J, Yuan HE, Franke EK, and Luban J: Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol 1996;70:4299-4310.
73. Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V, and Rosenwirth B: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: Interference with HIV protein-cyclophilin A interactions. J Virol 1995;69:2451-2461.
74. Camaur D and Trono D: Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996;70: 6106-6111.
75. Simon JH, Fouchier RAM, Southerling TE, Guerra CB, Grant CK, and Malim MH: The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol 1997;71:5259-5267.
76. Ewart GD, Sutherland T, Gage PW, and Cox GB: The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996;70:7108-7115.
77. Chen BK, Gandhi RT, and Baltimore D: CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of Vpu, Env, and Nef. J Virol 1996;70:6044-6053.
78. Piller SC, Ewart GD, Premkumar A, Cox GB, and Gage PW: Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc Natl Acad Sci USA 1996;93:111-115.
79. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, and Goudsmit J: pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997; 71:6348-6358.